Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer

Cancer Research

Volumn 70, Issue 16, 2010, Pages 6497-6508

  Cao, Liang ^a   Yu, Yunkai ^a,c   Bilke, Sven ^a   Walker, Robert L ^a   Mayeenuddin, Linnia H ^a,c   Azorsa, David O ^b,d   Yang, Fan ^a   Pineda, Marbin ^a   Helman, Lee J ^a   Meltzer, Paul S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; HYBRID PROTEIN; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; ANAPLASTIC LYMPHOMA KINASE; FGFR4 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; MYOD PROTEIN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PAX3-FKHR FUSION PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ARTICLE; BINDING SITE; CARCINOGENESIS; CONTROLLED STUDY; E BOX ELEMENT; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TRANSCRIPTION INITIATION SITE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; EWING SARCOMA; GENETICS; HUMAN GENOME; METABOLISM; REGULATORY SEQUENCE; TUMOR CELL LINE; UPREGULATION;

BINDING SITES; CELL LINE, TUMOR; E-BOX ELEMENTS; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MYOD PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTOR, IGF TYPE 1; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RHABDOMYOSARCOMA, ALVEOLAR; SARCOMA, EWING'S; TRANSCRIPTION INITIATION SITE; UP-REGULATION; RECEPTOR PROTEIN-TYROSINE KINASES; SARCOMA, EWING;

EID: 77955739897     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0582     Document Type: Article

References (50)

1. Blake JA, Thomas M, Thompson JA, White R, Ziman M. Perplexing Pax: from puzzle to paradigm. Dev Dyn 2008;23710:2791-803.
2. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol 2007;23:645-73.
3. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006;61:52-62.
4. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007;731:1-14.
5. Buckingham M. Skeletal muscle progenitor cells and the role of Pax genes. C R Biol 2007;3306-7:530-3.
6. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;2040:5736-46.
7. Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst 1983;701:49-55.
8. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;53:230-5.
9. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;32:113-7.
10. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995;153:1522-35.
11. Bennicelli JL, Advani S, Schafer BW, Barr FG. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999;1830:4348-56.
12. Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer BW, Buckingham M. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 2003;1723:2950-65.
13. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004;1821:2614-26.
14. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2002;2011:2672-9.
15. Goldhamer DJ, Faerman A, Shani M, Emerson CP, Jr. Regulatory elements that control the lineage-specific expression of myoD. Science 1992;256:538-42.
16. Goldhamer DJ, Brunk BP, Faerman A, King A, Shani M,Emerson CP, Jr. Embryonic activation of the myoD gene is regulated by a highly conserved distal control element. Development 1995;1213:637-49.
17. Bajard L, Relaix F, Lagha M, Rocancourt D, Daubas P, Buckingham ME. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. Genes Dev 2006;2017:2450-64.
18. Hadchouel J, Tajbakhsh S, Primig M, et al. Modular long-range regulation of Myf5 reveals unexpected heterogeneity between skeletal muscles in the mouse embryo. Development 2000;12720:4455-67.
19. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;6819:8039-48.
20. Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006;3811:1289-97.
21. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;1241:207-19.
22. Buchberger A, Freitag D, Arnold HH. A homeo-paired domain-binding motif directs Myf5 expression in progenitor cells of limb muscle. Development 2007;1346:1171-80.
23. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;6614:6936-46.
24. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009;1742:550-64.
25. Tapscott SJ, Weintraub H. MyoD and the regulation of myogenesis by helix-loop-helix proteins. J Clin Invest 1991;874:1133-8.
26. Kucharczuk KL, Love CM, Dougherty NM, Goldhamer DJ. Fine-scale transgenic mapping of the MyoD core enhancer: MyoD is regulated by distinct but overlapping mechanisms in myotomal and non-myotomal muscle lineages. Development 1999;1269:1957-65.
27. Tajbakhsh S, Rocancourt D, Cossu G, Buckingham M. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 1997;891:127-38.
28. Smith AD, Sumazin P, Zhang MQ. Identifying tissue-selective transcription factor binding sites in vertebrate promoters. Proc Natl Acad Sci U S A 2005;1025:1560-5.
29. Buckingham M. Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr Opin Genet Dev 2006;165:525-32.
30. Lagha M, Kormish JD, Rocancourt D, et al. Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev 2008;2213:1828-37.
31. Taylor JG, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009;11911:3395-407.
32. Epstein JA, Shapiro DN, Cheng J, Lam PY, Maas RL. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci U S A 1996;939:4213-8.
33. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;234:880-8.
34. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
35. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8.
36. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germ-line activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
37. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
38. Relaix F, Montarras D, Zaffran S, et al. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 2006;1721:91-102.
39. Relaix F, Rocancourt D, Mansouri A, Buckingham M. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 2005;435:948-53.
40. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999;9623:13264-9.
41. Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB. Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002;793:278-84.
42. Begum S, Emami N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005;2411:1860-72.
43. Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor α receptor. Mol Cell Biol 1998;187:4118-30.
44. Tarnowski M, Grymula K, Reca R, et al. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010;81:1-14.
45. Zhang L, Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene 2007;2611:1595-605.
46. Candia AF, Hu J, Crosby J, et al. Mox-1 and Mox-2 define a novel homeobox gene subfamily and are differentially expressed during early mesodermal patterning in mouse embryos. Development 1992;1164:1123-36.
47. Mankoo BS, Collins NS, Ashby P, et al. Mox2 is a component of the genetic hierarchy controlling limb muscle development. Nature 1999;400:69-73.
48. Martin JF, Bradley A, Olson EN. The paired-like homeo box gene MHox is required for early events of skeletogenesis in multiple lineages. Genes Dev 1995;910:1237-49.
49. Conway SJ, Henderson DJ, Copp AJ. Pax3 is required for cardiac neural crest migration in the mouse: evidence from the splotch (Sp2H) mutant. Development 1997;1242:505-14.
50. Mercado GE, Xia SJ, Zhang C, et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 2008;476:510-20.